GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 208 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $116,220,000 | +440.4% | 1,706,600 | +153.5% | 0.03% | +440.0% |
Q2 2022 | $21,508,000 | -66.1% | 673,167 | -63.3% | 0.01% | -61.5% |
Q1 2022 | $63,520,000 | +75.3% | 1,833,720 | +48.2% | 0.01% | +85.7% |
Q4 2021 | $36,229,000 | +83.2% | 1,237,737 | +59.5% | 0.01% | +75.0% |
Q3 2021 | $19,776,000 | -15.2% | 776,157 | +16.5% | 0.00% | -20.0% |
Q2 2021 | $23,323,000 | +21.5% | 665,990 | +41.4% | 0.01% | 0.0% |
Q1 2021 | $19,191,000 | -52.3% | 470,949 | -49.3% | 0.01% | -50.0% |
Q4 2020 | $40,194,000 | +27.8% | 928,048 | +62.7% | 0.01% | +11.1% |
Q3 2020 | $31,448,000 | -18.8% | 570,318 | -7.1% | 0.01% | -25.0% |
Q2 2020 | $38,740,000 | -5.2% | 613,654 | -23.3% | 0.01% | -14.3% |
Q1 2020 | $40,859,000 | -9.4% | 799,757 | +41.0% | 0.01% | +27.3% |
Q4 2019 | $45,080,000 | +122.0% | 567,112 | +35.5% | 0.01% | +83.3% |
Q3 2019 | $20,310,000 | -34.4% | 418,586 | -28.8% | 0.01% | -25.0% |
Q2 2019 | $30,945,000 | +13.5% | 588,312 | +14.2% | 0.01% | 0.0% |
Q1 2019 | $27,273,000 | +54.9% | 515,276 | +20.1% | 0.01% | +33.3% |
Q4 2018 | $17,606,000 | +9.1% | 428,902 | +1.0% | 0.01% | +50.0% |
Q3 2018 | $16,138,000 | -23.0% | 424,678 | -8.5% | 0.00% | -20.0% |
Q2 2018 | $20,969,000 | -2.0% | 463,925 | +4.7% | 0.01% | 0.0% |
Q1 2018 | $21,401,000 | +81.7% | 443,072 | +48.0% | 0.01% | +66.7% |
Q4 2017 | $11,779,000 | +25.8% | 299,335 | -0.8% | 0.00% | +50.0% |
Q3 2017 | $9,365,000 | +7.8% | 301,617 | -5.0% | 0.00% | 0.0% |
Q2 2017 | $8,686,000 | +131.4% | 317,571 | +211.7% | 0.00% | +100.0% |
Q1 2017 | $3,754,000 | +555.1% | 101,881 | +157.0% | 0.00% | – |
Q4 2016 | $573,000 | -49.6% | 39,650 | -42.1% | 0.00% | – |
Q2 2016 | $1,137,000 | -88.6% | 68,529 | -89.1% | 0.00% | -100.0% |
Q1 2016 | $9,974,000 | +1148.3% | 628,859 | +2443.9% | 0.00% | – |
Q4 2015 | $799,000 | +215.8% | 24,720 | +312.1% | 0.00% | – |
Q3 2015 | $253,000 | – | 5,999 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |